What question did this study set out to answer?

To examine and compare the receptor binding kinetics, pharmacokinetics, and clinical antihypertensive efficacy among different angiotensin II receptor blockers.

January 1, 2000American Journal of HypertensionOpen Access

Newly emerging pharmacologic differences in angiotensin II receptor blockers

View Full Paper

Ask AI

Bookmark

Why the study?

Do different angiotensin II receptor blockers differ in their pharmacologic properties and blood pressure lowering efficacy in patients with mild to moderate hypertension?

Population

Patients with mild to moderate hypertension

Comparison

Angiotensin II receptor blockers including… vs Other ARBs

Design

Review

Authors

SOSuzanne OparilUniversity of Alabama at Birmingham

Discussion

Member takes

Implication

Should not yet change ARB selection in hypertension; leaves open whether pharmacologic differences affect outcomes.

Key Points

To examine and compare the receptor binding kinetics, pharmacokinetics, and clinical antihypertensive efficacy among different angiotensin II receptor blockers.
Evaluated AT1 receptor affinity and mechanisms of antagonism (insurmountable versus competitive) across multiple ARBs, including candesartan, irbesartan, losartan, valsartan, and eprosartan.
Assessed pharmacokinetic profiles, focusing on prodrug metabolism, oral bioavailability, route of elimination, and elimination half-lives.
Reviewed initial comparative clinical trial data regarding once-daily dosing efficacy on trough sitting diastolic blood pressure in mild-to-moderate hypertension.
Candesartan displays the highest AT1 receptor affinity, with candesartan and irbesartan acting as insurmountable antagonists, while losartan, valsartan, and eprosartan act as competitive antagonists.
Candesartan cilexetil and irbesartan have longer elimination half-lives compared to shorter-acting agents (losartan, valsartan, and eprosartan).
Initial comparative clinical trials show that candesartan cilexetil and irbesartan achieve significantly greater reductions in trough sitting diastolic blood pressure compared to losartan.

Structured PICO

Do different angiotensin II receptor blockers differ in their pharmacologic properties and blood pressure lowering efficacy in patients with mild to moderate hypertension?

Population

Patients with mild to moderate hypertension

Intervention

Angiotensin II receptor blockers (ARBs) including candesartan, irbesartan, losartan, valsartan, and eprosartan

Comparator

Other ARBs (e.g., losartan vs candesartan/irbesartan)

Outcome

Blood pressure lowering (trough sitting diastolic blood pressure)surrogate

While ARBs share a common mechanism, they exhibit distinct pharmacokinetic and pharmacodynamic profiles that may translate to differences in blood pressure lowering efficacy, though impact on long-term outcomes remains unclear.

Limitations

Unknown whether pharmacologic differences impact long-term cardiovascular outcomes and mortality

Cite This Study

Suzanne Oparil (2000) studied this question.

synapsesocial.com/papers/6a7d187e166e996abdd5a1c5 https://doi.org/10.1016/s0895-7061(99)00250-2

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Newly emerging pharmacologic differences in angiotensin II receptor blockers

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

Newly emerging pharmacologic differences in angiotensin II receptor blockers

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider